Oren Gilad
Known title: President, CEOCIK: 0001929300
Oren Gilad's purchase track record
How the stock did after each of Oren Gilad's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
5
of 5 since March 13, 2024
Stock higher 6 months later
0%
3 months: 60%
Median 6-month return
-39.0%
3 months: +2.8%
Beat the S&P 500
0%
median -42.2% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/30/2026 | APRE | $25K | +2.8% | -22.1% | +7.9% |
| 4/3/2025 | APRE | $10K | -3.3% | -17.8% | +24.4% |
| 10/23/2024 | APRE | $2K | +2.8% | -61.5% | -7.3% |
| 10/10/2024 | APRE | $4K | +43.9% | -39.0% | -8.9% |
| 3/13/2024 | APRE | $15K | -22.2% | -42.0% | +7.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| APRE | ▲ Buy | Grant | 20,175 | $0 | 3/12/2026 | View on chart |
| APRE | ▲ Buy | Open Market | 28,100 | $25K | 1/30/2026 | View on chart |
| APRE | ▲ Buy | Open Market | 3,003 | $6K | 4/3/2025 | View on chart |
| APRE | ▲ Buy | Open Market | 2,497 | $4K | 4/3/2025 | View on chart |
| APRE | ▲ Buy | Grant | 6,725 | $0 | 3/27/2025 | View on chart |
| APRE | ▲ Buy | Open Market | 500 | $2K | 10/23/2024 | View on chart |
| APRE | ▲ Buy | Open Market | 250 | $725 | 10/15/2024 | View on chart |
| APRE | ▲ Buy | Open Market | 1,000 | $3K | 10/14/2024 | View on chart |
| APRE | ▲ Buy | Open Market | 150 | $381 | 10/10/2024 | View on chart |
| APRE | ▲ Buy | Grant | 6,725 | $0 | 3/28/2024 | View on chart |
| APRE | ▲ Buy | Open Market | 2,000 | $15K | 3/13/2024 | View on chart |
| APRE | ▲ Buy | Grant | 4,000 | $0 | 3/9/2023 | View on chart |
| APRE | ▼ Sell | Other | 6,045,100 | $0 | 8/23/2022 | View on chart |
| APRE | ▲ Buy | Grant | 101,300 | $0 | 7/28/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Aprea Therapeutics Announces October Conference Presentations
Aprea Therapeutics will present at several conferences in October. The company’s appearance is intended to share progress on its research and development efforts. The presentation may offer new information to investors and analysts about the company’s pipeline and strategy. The event is a routine update for the company’s stakeholders.
Aprea Therapeutics Announces October Conference Presentations. Aprea Therapeutics will present at several conferences in October. The company’s appearance is intended to share progress on its research and development efforts. The presentation may offer new information to investors and analysts about the company’s pipeline and strategy. The event is a routine update for the company’s stakeholders.